Gut: The Gene Set of Machine Learning Model to Identify the Survival Benefit of Paclitaxel in Gastric Cancer: Data Analysis from the Phase III Randomized Clinical Trial SAMIT

Gastric cancer is a common malignant tumor.

Gastric cancer is a common malignant tumor.

The study is based on the analysis of the phase III randomized clinical trial SAMIT.

Methods: Firstly, SAMIT gastric cancer was selected as the experimental group, and the Pac-S-1 group was used as the training cohort.

Methods: Firstly, SAMIT gastric cancer was selected as the experimental group, and the Pac-S-1 group was used as the training cohort.

Research data showed that 499 patients from the SAMIT study were finally analyzed.

Comparison of survival between the two groups in the paclitaxel-UFT group

In the independent Pac-Ram cohort verification, the paclitaxel-sensitive group identified by the gene set had significantly longer PFS (median PFS 147 days vs 112 days, HR 0.

In the independent Pac-Ram cohort validation, the paclitaxel-sensitive group identified by the gene set had significantly longer PFS (median PFS 147 days vs 112 days, HR 0.

Comparison of survival between the two groups in the Pac-Ram cohort

Next, the researchers verified on the TCGA data set that TCGA classified gastric cancer into chromosomal instability (CIN), genome stable (GS), microsatellite instability and EBV positive.

Next, the researchers verified on the TCGA data set that TCGA classified gastric cancer into chromosomal instability (CIN), genome stable (GS), microsatellite instability and EBV positive.

TCGA database verification

In summary, this study used machine learning model to identify markers of paclitaxel benefit through gastric cancer large-scale clinical trial data for the first time.

In summary, this study used machine learning model to identify markers of paclitaxel benefit through gastric cancer large-scale clinical trial data for the first time.
This study is the first to use machine learning models to identify markers of paclitaxel benefit through gastric cancer large-scale clinical trial data.
This study is the first to use machine learning models to identify markers of paclitaxel benefit through gastric cancer large-scale clinical trial data.

Original source:

Original source:

Sundar R, Barr Kumarakulasinghe N, Huak Chan Y, et al.
Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial.
Gut.
2021 May 12; gutjnl-2021-324060 .
doi: 10.
1136/gutjnl-2021-324060.
Online ahead of print.

Sundar R, Barr Kumarakulasinghe N, Huak Chan Y, et al.
Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial.
Gut.
2021 May 12; gutjnl-2021-324060 .
doi: 10.
1136/gutjnl-2021-324060.
Online ahead of print.


Leave a message here